Andrew A. F. Hack - 12 Jun 2024 Form 4 Insider Report for Nuvalent, Inc. (NUVL)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
14 Jun 2024, 16:53:35 UTC
Prior SEC filing
12 Jun 2024
Next SEC filing
13 Dec 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Andrew Hack

Key filing fact

Andrew A. F. Hack filed Form 4 for Nuvalent, Inc. (NUVL) on 14 Jun 2024.

Key facts

  • This page summarizes Andrew A. F. Hack's Form 4 filing for Nuvalent, Inc. (NUVL).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 14 Jun 2024, 16:53.

Change

  • Previous filing in this sequence was filed on 12 Jun 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NUVL transaction

Class A Common Stock

Award

Transaction value
Shares
+2,499
Change %
Price
Shares after
2,499
Date
12 Jun 2024
Ownership
Direct
Footnotes
F1
NUVL holding

Class A Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
2,697,267
Date
12 Jun 2024
Ownership
See footnotes
Footnotes
F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NUVL transaction Derivative

Stock Option (right to buy)

Award

Transaction value
$0
Shares
+3,789
Change %
Price
$0.000000
Shares after
3,789
Date
12 Jun 2024
Ownership
Direct
Underlying class
Class A Common Stock
Underlying amount
3,789
Exercise price
$80.03
Footnotes
F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The shares reported in this transaction represent Restricted Stock Units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Class A Common Stock. 100% of the RSUs subject to this grant will vest on the earlier of June 12, 2025 or the date of the Issuer's next annual meeting of stockholders, subject to continued service to the Issuer through such vesting date.

Footnote F2

The shares underlying this option will vest in full on the earlier of June 12, 2025 or the date of the Issuer's next annual meeting of stockholders, subject to continued service to the Issuer through such vesting date.

Footnote F3

Represents shares of Class A Common Stock held directly by Bain Capital Life Sciences Fund II, L.P. ("BCLS Fund II"), BCIP Life Sciences Associates, LP ("BCIPLS") and BCLS II Investco, LP ("BCLS II Investco" and, together with BCLS Fund II and BCIPLS, the "Bain Capital Life Sciences Entities").

Footnote F4

Bain Capital Life Sciences Investors, LLC ("BCLSI") is the ultimate general partner of each of BCLS Fund II and BCLS II Investco and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Partner of BCLSI. By virtue of the relationships described in this footnote, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .